Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study

被引：91
|
作者：
Qin, Shukui
Chen, Zhendong
Fang, Weijia
Ren, Zhenggang
Xu, Ruocai
Ryoo, Baek-Yeol
Meng, Zhiqiang
Bai, Yuxian
Chen, Xiaoming
Liu, Xiufeng
Xiao, Juxiang
Ho, Gwo Fuang
Mao, Yimin
Ye, Xing
Ying, Jieer
Li, Jianfeng
Zhong, Wen Yan
Zhou, Yu
Siegel, Abby B.
Hao, Chunyi
机构：
[1] Nanjing Chinese Med Univ, Jinling Hosp, Ctr Canc, Nanjing, Peoples R China
[2] Anhui Med Univ, Hosp 2, Hefei, Peoples R China
[3] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[5] Hunan Canc Hosp, Changsha, Peoples R China
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[7] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[8] Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China
[9] Guangdong Prov Peoples Hosp, Dept Intervent Radiol, Guangzhou, Peoples R China
[10] Chinese PLA, Eastern Theater Gen Hosp, Nanjing, Peoples R China
[11] Xi An Jiao Tong Univ, Affiliated Hosp 1, Shaaxi, Peoples R China
[12] Univ Malaya, Dept Clin Oncol, Fac Med, Kuala Lumpur, Malaysia
[13] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai, Peoples R China
[14] Deyang Hosp, Deyang, Peoples R China
[15] Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp,Inst Canc & Basic Med IBMC, Hangzhou, Zhejiang, Peoples R China
[16] MSD China, Beijing, Peoples R China
[17] MSD China, Shanghai, Peoples R China
[18] Columbia Univ, New York, NY USA
[19] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.383
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
383
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
    Qin, Shukui
    Fang, Weijia
    Ren, ZhengGang
    Shuangyan, Ou
    Lim, Ho Yeong
    Zhang, Feng
    Choi, Hye Jin
    Tong, Jiandong
    Tao, Min
    Xu, Aibing
    Cheng, Ashley Chi Kin
    Lu, Chang-Hsien
    Chiu, Chang-Fang
    Wahid, Mohamed Ibrahim A.
    Kamble, Shital
    Norquist, Josephine M.
    Zhong, Wen Yan
    Li, Chen
    Chen, Zhendong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
    Abou-Alfa, G. K.
    Qin, S.
    Ryoo, B-Y.
    Lu, S-N.
    Yen, C-J.
    Feng, Y-H.
    Lim, H. Y.
    Izzo, F.
    Colombo, M.
    Sarker, D.
    Bolondi, L.
    Vaccaro, G.
    Harris, W. P.
    Chen, Z.
    Hubner, R. A.
    Meyer, T.
    Sun, W.
    Harding, J. J.
    Hollywood, E. M.
    Ma, J.
    Wan, P. J.
    Ly, M.
    Bomalaski, J.
    Johnston, A.
    Lin, C-C.
    Chao, Y.
    Chen, L-T.
    ANNALS OF ONCOLOGY, 2018, 29 (06) : 1402 - 1408
  • [3] Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Qin, Shukui
    Ryoo, Baek-Yeol
    Lu, Sheng-Nan
    Yen, Chia-Jui
    Feng, Yin-Hsun
    Lim, Ho Yeong
    Izzo, Francesco
    Colombo, Massimo
    Sarker, Debashis
    Bolondi, Luigi
    Vaccaro, Gina M.
    Harris, William Proctor
    Chen, Zhendong
    Hubner, Richard
    Meyer, Tim
    Bomalaski, John S.
    Lin, ChenChun
    Chao, Yee
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
    Chan, S. L.
    Finn, R. S.
    Zhu, A. X.
    Knox, J.
    Cheng, A-L.
    Siegel, A. B.
    Bautista, O.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
    Kang, Y. -K.
    Yau, T.
    Park, J. -W.
    Lim, H. Y.
    Lee, T. -Y.
    Obi, S.
    Chan, S. L.
    Qin, S. K.
    Kim, R. D.
    Casey, M.
    Chen, C.
    Bhattacharyya, H.
    Williams, J. A.
    Valota, O.
    Chakrabarti, D.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2457 - 2463
  • [6] Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study
    Finn, R.
    Chan, S. L.
    Zhu, A. X.
    Knox, J.
    Cheng, A-L.
    Siegel, A.
    Bautista, O.
    Watson, P. A.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.
    Finn, Richard S.
    Chan, Stephen L.
    Zhu, Andrew X.
    Knox, Jennifer J.
    Cheng, Ann-Lii
    Siegel, Abby B.
    Bautista, Oliver
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)
    Finn, R. S.
    Chan, S. L.
    Zhu, A. X.
    Knox, J.
    Cheng, A-L.
    Siegel, A. B.
    Bautista, O.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.
    Finn, Richard S.
    Chan, Stephen L.
    Zhu, Andrew X.
    Knox, Jennifer J.
    Cheng, Ann-Lii
    Siegel, Abby B.
    Bautista, Oliver
    Watson, Pat
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [10] Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Ryoo, Baek-Yeol
    Merle, Philippe
    Kudo, Masatoshi
    Bouattour, Mohamed
    Lim, Ho-Yeong
    Breder, Valeriy Vladimirovich
    Edeline, Julien
    Chao, Yee
    Ogasawara, Sadahisa
    Yau, Thomas
    Garrido, Marcelo
    Chan, Stephen Lam
    Knox, Jennifer J.
    Daniele, Bruno
    Ebbinghaus, Scot
    Chen, Erluo
    Siegel, Abby B.
    Zhu, Andrew X.
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345